K-pop’s evolution into global cultural identity highlights its power to transcend borders and connect diverse audiences K-pop ...

SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- LPL Financial LLC announced today that father and son financial advisors Bart Lewellyn and Alex Lewellyn have joined LPL Financial’s broker-dealer, RIA and ...

NDAQ:INTS) Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6 ...

By Zhang ZhenConsul General of the People’s Republic of China in Cebu Dec. 30 is Rizal Day. Dr. José Rizal had a vision for ...

This valuable study relating brain anatomy to reading ability in children studied longitudinally finds that a difference in sulcal anatomy is more predictive of reading ability than cognitive measures ...

Medically reviewed by Nicholas R. Metrus, MD A person’s brain is not fully developed until their mid to late 20s, as the ...

In 2024, the world witnessed further transformation and instability, marked by protracted and intensified geopolitical ...

Fighters of Turkish-supported forces are positioned on the Buwayhij-Boughaz-Korhoyuk front on the outskirts of Manbij in northeastern Syria as they fight with the Kurdish-led Syrian Democratic Forces ...

Immunovant plans pivotal study for IMVT-1402 targeting Graves' Disease. Financial caution advised due to its limited cash ...

The company is focused on developing medicines for immune-mediated diseases. The stock currently trades around $4.75 a share and sports an approximate market capitalization of just under $300 million.

About NEXICART-2 NEXICART-2 (NCT06097832) is an open-label, single-arm, multi-site U.S. Phase 1b/2 dose expansion clinical trial of CAR-T NXC-201 in relapsed/refractory AL Amyloidosis. NEXICART-2 ...